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The ability to assess the distribution and extent of tau pathology in Alzheimer’s disease and progressive supranuclear palsy in vivo
would help to develop biomarkers for these tauopathies and clinical trials of disease-modifying therapies. New radioligands for
positron emission tomography have generated considerable interest, and controversy, in their potential as tau biomarkers. We
assessed the radiotracer 18F-AV-1451 with positron emission tomography imaging to compare the distribution and intensity of tau
pathology in 15 patients with Alzheimer’s pathology (including amyloid-positive mild cognitive impairment), 19 patients with
progressive supranuclear palsy, and 13 age- and sex-matched controls. Regional analysis of variance and a support vector machine
were used to compare and discriminate the clinical groups, respectively. We also examined the 18F-AV-1451 autoradiographic
binding in post mortem tissue from patients with Alzheimer’s disease, progressive supranuclear palsy, and a control case to assess
the 18F-AV-1451 binding speciﬁcity to Alzheimer’s and non-Alzheimer’s tau pathology. There was increased 18F-AV-1451 binding
in multiple regions in living patients with Alzheimer’s disease and progressive supranuclear palsy relative to controls [main effect of
group, F(2,41) = 17.5, P50.0001; region of interest  group interaction, F(2,68) = 7.5, P50.00001]. More speciﬁcally, 18F-AV-
1451 binding was signiﬁcantly increased in patients with Alzheimer’s disease, relative to patients with progressive supranuclear
palsy and with control subjects, in the hippocampus and in occipital, parietal, temporal, and frontal cortices (t’s4 2.2, P’s5 0.04).
Conversely, in patients with progressive supranuclear palsy, relative to patients with Alzheimer’s disease, 18F-AV-1451 binding was
elevated in the midbrain (t = 2.1, P5 0.04); while patients with progressive supranuclear palsy showed, relative to controls,
increased 18F-AV-1451 uptake in the putamen, pallidum, thalamus, midbrain, and in the dentate nucleus of the cerebellum
(t’s4 2.7, P’s5 0.02). The support vector machine assigned patients’ diagnoses with 94% accuracy. The post mortem autoradio-
graphic data showed that 18F-AV-1451 strongly bound to Alzheimer-related tau pathology, but less speciﬁcally in progressive
supranuclear palsy. 18F-AV-1451 binding to the basal ganglia was strong in all groups in vivo. Postmortem histochemical staining
showed absence of neuromelanin-containing cells in the basal ganglia, indicating that off-target binding to neuromelanin is an
insufﬁcient explanation of 18F-AV-1451 positron emission tomography data in vivo, at least in the basal ganglia. Overall, we
conﬁrm the potential of 18F-AV-1451 as a heuristic biomarker, but caution is indicated in the neuropathological interpretation of
its binding. Off-target binding may contribute to disease proﬁles of 18F-AV-1451 positron emission tomography, especially in
primary tauopathies such as progressive supranuclear palsy. We suggest that 18F-AV-1451 positron emission tomography is a
useful biomarker to assess tau pathology in Alzheimer’s disease and to distinguish it from other tauopathies with distinct clinical
and pathological characteristics such as progressive supranuclear palsy.
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Introduction
Alzheimer’s disease and progressive supranuclear palsy
(PSP) are both associated with abnormal accumulation of
misfolded and aggregated tau protein. In Alzheimer’s dis-
ease, oligomeric and aggregated neuroﬁbrillary tau tangles
are a major determinant of synaptic/cell dysfunction and
death (Goedert et al., 1988; Ballatore et al., 2007; de
Calignon et al., 2012), notwithstanding the importance of
amyloid-b in its ‘toxic alliance’ with pathological tau
(Bloom, 2014). The intensity and distribution of tau in
Alzheimer’s disease also correlates with the clinical syn-
drome and severity and has been considered as one of
the primary factors in the neuropathological staging of
Alzheimer’s disease (Braak et al., 2006; Murray et al.,
2014; Ossenkoppele et al., 2015).
In patients with PSP and in analogous murine models,
intra-neuronal and astrocytic aggregates of pathological
tau isoforms (in the form of straight ﬁlaments) characterize
and promote neurodegeneration (Clavaguera et al., 2013).
Furthermore, tau pathology is common in other neuro-
logical diseases such as fronto-temporal dementia (Hodges
et al., 2004), corticobasal degeneration, and may modulate
the course of Parkinson’s disease (Spillantini and Goedert,
2001; Irwin et al., 2013), Huntington’s disease (Ferna´ndez-
Nogales et al., 2014), and multiple sclerosis (Anderson
et al., 2008).
Despite the importance of tau pathology in several neuro-
logical diseases, it has only recently become possible to
assess it using brain imaging in living humans. To be
able to measure the burden and distribution of tau path-
ology in living patients, or those at high risk of developing
tau-related disorders, would be a major step forward in the
development of disease-modifying therapies targeting the
tau protein. Speciﬁc markers could also enable pathological
characterization of syndromes associated with multiple al-
ternate pathologies, such as frontotemporal dementia and
corticobasal degeneration (Alexander et al., 2014). Such
biomarkers would ultimately need to be assessed in longi-
tudinal studies and clinical trials, but cross-sectional studies
can assess critical properties such as sensitivity to the pres-
ence of different diseases and the expected distribution of
pathology.
Radioligands have recently been developed for PET to
measure in vivo binding to aggregated tau, including
PBB3 (Maruyama et al., 2013), THK compounds
(Okamura et al., 2014), and 18F-AV-1451 (Chien et al.,
2013; Xia et al., 2013). In autoradiographic studies with
post mortem human brain tissues, the radiotracer 18F-AV-
1451 co-localizes selectively with hyperphosphorylated tau
over amyloid-b plaques (Marquie´ et al., 2015). In patients
with mild cognitive impairment (MCI) and Alzheimer’s dis-
ease, there is higher 18F-AV-1451 binding in frontal, par-
ietal, and temporal cortices relative to age-matched healthy
controls (Okello et al., 2009). Progressively increasing re-
gional 18F-AV-1451 binding in Alzheimer’s disease has also
been associated with Braak staging of neuroﬁbrillary tau
pathology (Scho¨ll et al., 2016; Schwarz et al., 2016),
while 18F-AV-1451 PET binding patterns mirror the clinical
and neuro-anatomical variability in the Alzheimer’s disease
spectrum (Ossenkoppele et al., 2016). Speciﬁcally, patients
with the amnestic presentation of Alzheimer’s disease
showed the highest 18F-AV-1451 uptake in medial tem-
poral lobe regions including the hippocampus, while pa-
tients with the logopenic variant of Alzheimer’s disease
displayed increased left hemispheric 18F-AV-1451 binding,
particularly in posterior temporo-parietal areas implicated
in linguistic processes (Ossenkoppele et al., 2016).
Performance on domain-speciﬁc neuro-psychological tests
was also associated with increased 18F-AV-1451 uptake
in brain regions involved in episodic memory, visuo-spatial
skills, and language production or comprehension
(Ossenkoppele et al., 2016).
Nevertheless, critical issues remain unresolved, and in
particular the value of 18F-AV-1451 in differentiating
distinct tauopathies as well as the speciﬁcity of binding to tau
as veriﬁed through pathological analyses. Neuropathological
data with autoradiography have suggested that the
18F-AV-1451 tracer displays strong binding to paired
helical ﬁlaments characteristic of Alzheimer’s disease
(e.g. intra-neuronal and extra-neuronal neuroﬁbrillary
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tangles and dystrophic neurites), but it does not bind so
speciﬁcally to the straight tau ﬁlaments that are more typical
of PSP and non-Alzheimer’s disease tauopathies (e.g. cor-
tico-basal degeneration) (Marquie´ et al., 2015). However,
we have recently found that 18F-AV-1451 binds to regions
of pathology (i.e. frontal and temporal cortices) in a patient
with a MAPT gene mutation leading to straight tau ﬁla-
ments and non-Alzheimer’s disease dementia (Bevan-Jones,
2016b). It has also been proposed that the 18F-AV-1451
tracer displays off-target binding, speciﬁcally to neuromela-
nin-containing cells. This was supported by evidence in pa-
tients with Parkinson’s disease, in vivo, in the midbrain;
and post mortem, in retinal and brain tissues in porcine
and rodent models (Hansen et al., 2016).
In this study, we sought to evaluate the utility of 18F-AV-
1451 PET imaging in Alzheimer’s disease versus non-
Alzheimer’s disease tauopathies. We used dynamic PET ima-
ging with kinetic modelling, rather than standardized uptake
value ratios (SUVR), in part to accommodate variations in
cerebral perfusion that can reduce reliability of SUVR. We
aimed to identify the patterns of 18F-AV-1451 uptake in
patients with Alzheimer’s disease and contrast these patterns
with those that were expected in patients with PSP on the
basis of previous studies (Johnson et al., 2016; Ossenkoppele
et al., 2016; Scho¨ll et al., 2016; Schwarz et al., 2016).
The value of comparing these two clinical groups lies not
in their differential diagnosis, which is clear on clinical
grounds alone, but in testing the ligand’s binding against
well-established clinico-pathological correlations and dis-
tinct distributions of tau pathology. These two disorders
represent different kinds of tauopathy, with paired helical
versus straight ﬁlamentous tau. Evidence on 18F-AV-1451’s
binding distributions, its off-target binding, and clinical
correlations would directly inform the design of forthcom-
ing clinical trials of anti-tau therapies in these diseases.
Overall, we aimed to: (i) identify the patterns of 18F-AV-
1451 binding in patients with Alzheimer’s disease, relative to
patients with PSP as well as sex- and age-matched healthy
controls; (ii) test whether 18F-AV-1451 binding was associated
with disease severity in Alzheimer’s disease and PSP; and (iii)
assess whether regional 18F-AV-1451 binding could distin-
guish between Alzheimer’s disease and PSP groups. We com-
bined patients with clinical diagnostic criteria for Alzheimer’s
disease and MCI patients who had biomarker evidence of
Alzheimer’s disease pathology (i.e. with a positive scan for
amyloid), based on the fact that these two groups represent
a continuum of disease (Okello et al., 2009). In view of the
suggested effect of off-target binding, we also examined 18F-
AV-1451 uptake in relation to AT8 immunohistochemistry of
hyperphosphorylated tau protein and tinctorial stain for neu-
romelanin, in post mortem sections from a patient with
Alzheimer’s disease, PSP, and a similarly aged control from
the Cambridge Brain Bank.
Our principal hypotheses were that: (i) patients with
Alzheimer’s disease and those with MCI and PET scans posi-
tive for amyloid would show increased 18F-AV-1451 binding
in the cortical and subcortical areas associated with
Alzheimer’s pathology, including the medial temporal lobe
as well as frontal, parietal, and temporal cortices (Serrano-
Pozo et al., 2011); (ii) patients with PSP would display
increased 18F-AV-1451 binding especially in the midbrain
and basal ganglia, with likely additional binding in frontal
cortex (including the motor areas) and supramarginal gyrus,
a set of subcortical and cortical regions that have been shown
to display tau pathology in PSP (Schoﬁeld et al., 2005;
Dickson et al., 2007; Smith et al., 2016); and (iii) PSP and
Alzheimer’s disease patients would be distinguishable based
on the regional 18F-AV-1451 binding levels, particularly in
the hippocampus and midbrain, two key subcortical regions
that show highly distinct neuropathological changes in
Alzheimer’s disease and PSP, respectively.
Materials and methods
Participants
The current study was conducted within the context of the
Neuroimaging of Inﬂammation in MemoRy and Other
Disorders (NIMROD) project (Bevan-Jones et al., 2016a). We
recruited 19 patients with PSP [‘probable PSP’ by Movement
Disorder Society criteria (Litvan et al., 1996a, b), representing
the ‘classical phenotype’, which is sometimes referred to as
Richardson’s syndrome], nine patients meeting diagnostic criteria
for probable Alzheimer’s disease (McKhann et al., 2011), and six
patients with MCI and biomarker evidence of Alzheimer’s disease
(i.e. amyloid pathology). MCI was deﬁned as a Mini-Mental
Score Examination (MMSE) 424 with a memory impairment
at least 1.5 standard deviations (SD) below that expected for
age and education (Petersen et al., 1999). All participants with
MCI had a positive Pittsburgh compound B (PiB) PET scan (as-
sessing in vivo amyloid pathology). Thirteen age- and sex-
matched healthy controls with no history of major psychiatric
or neurological illnesses, head injury or any other signiﬁcant med-
ical co-morbidity were also included to allow group-wise com-
parisons with the clinical cohorts. All participants were aged over
50 years, had sufﬁcient proﬁciency in English for cognitive testing
and had no contraindications to MRI. Patients and healthy con-
trols were identiﬁed from the specialist clinics for memory dis-
orders and PSP at the Cambridge University Hospitals NHS Trust
and from registers held by the Dementias and Neurodegenerative
Diseases Research Network (DeNDRoN); part of the NIHR
Clinical Research Network. All participants had full mental cap-
acity and provided written informed consent which was approved
by the local ethical committee, in accord to the Declaration of
Helsinki. As some of the assessment scales required carers’ input




Clinical and cognitive assessment
Participants underwent an initial assessment that included clin-
ical indices of disease severity (e.g. Progressive Supranuclear
Palsy Rating Scale) (Golbe and Ohman-Strickland, 2007),
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demographic measures, and neuropsychological tests [MMSE
and Addenbrooke’s Cognitive Examination-Revised (ACE-R)].
MRI data acquisition and preprocessing
Participants underwent an MRI session acquired on a 3 T
scanner (Siemens Magnetom Tim Trio and Verio scanner;
www.medical.siemens.com) using a MP-RAGE T1-weighted se-
quence (all groups). The T1-weighted sequence (repetition
time = 2300 ms, echo time = 2.98ms, ﬁeld of
view = 240  256mm2, 176 slices of 1mm thickness, ﬂip
angle = 9) was used to facilitate tissue class segmentation
(grey and white matter, together with CSF), and to allow
non-rigid registration of standard space regions of interest
(using a modiﬁed version of the Hammers atlas that included
the midbrain and dentate nucleus of the cerebellum) (Hammers
et al., 2003) to subject MRI space. Each T1 image was non-
rigidly registered to the ICBM2009a template brain using
ANTS (http://www.picsl.upenn.edu/ANTS/) and the inverse
transform was applied to the Hammers atlas (resliced from
MNI152 to ICBM2009a space) to bring the regions of interest
to subject MRI space.
PET data acquisition and
preprocessing
All participants (i.e. patients with Alzheimer’s disease, with MCI,
with PSP, and control subjects) underwent 18F-AV-1451 PET
imaging to assess the extent and intensity of brain tau pathology.
Subjects with MCI also underwent 11C-PiB PET imaging to assess
the density of amyloid-b deposits as an indication of Alzheimer’s
disease amyloid pathology. All radioligands were prepared at the
Wolfson Brain Imaging Centre (WBIC), University of Cambridge,
with high radiochemical purity (495%). 11C-PiB was produced
with speciﬁc activity of 4150 GBq/mmol, while 18F-AV-1451
speciﬁc activity was of 216  60 GBq/mmol at the end of synthe-
sis. PET scanning was performed on a GE Advance PET scanner
(GE Healthcare) and a GE Discovery 690 PET/CT. A 15-min
68Ge/68Ga transmission scan was used for attenuation correction
on the Advance, which was replaced by a low dose CT scan on
the Discovery 690. The emission protocols were the same on
both scanners: 550 MBq 11C-PiB injection followed by imaging
from 40–70min post-injection and 90min dynamic imaging (58
frames) following a 370 MBq 18F-AV-1451 injection.
Each emission frame was reconstructed using the PROMIS 3D
ﬁltered back projection algorithm into a 128  128 matrix 30 cm
transaxial ﬁeld of view, with a transaxial Hann ﬁlter cut-off at
the Nyquist frequency (Kinahan and Rogers, 1989). Corrections
were applied for randoms, dead time, normalization, scatter, at-
tenuation, and sensitivity. Each emission image series was aligned
using SPM8 to correct for patient motion during data acquisition
(www.ﬁl.ion.ucl.ac.uk/spm/software/spm8).
The mean aligned PET image, and hence the corresponding
aligned dynamic PET image series, was rigidly registered to the
T1-weighted image using SPM8 to extract values from both the
Hammers atlas regions of interest and those in a reference
tissue deﬁned in the superior grey matter of the cerebellum
using a 90% grey matter threshold on the grey matter prob-
ability map produced by SPM8 smoothed to PET resolution.
The superior cerebellum was used as reference region as it is
considered to have little or no tau pathology in either PSP or
Alzheimer’s disease (Williams et al., 2007; Okello et al., 2009;
Dickson, 2010; Scho¨ll et al., 2016; Schwarz et al., 2016). This
was conﬁrmed in our post-mortem cases (Supplementary ma-
terial). All region of interest data, including the reference tissue
values, were corrected for CSF partial volumes through div-
ision with the mean region of interest probability (normalized
to 1) of grey plus white matter segments, each smoothed to
PET resolution. To test whether correction for CSF affected
the main results, we repeated all the 18F-AV-1451 PET ana-
lyses using data not corrected for CSF (see ‘PET statistical
analyses’ and ‘Results’ sections).
11C-PiB data were quantiﬁed using SUVR by dividing the
mean CSF-corrected radioactivity concentration in each
region of interest by the corresponding mean radioactivity con-
centration in the reference tissue region of interest (whole cere-
bellum). For 18F-AV-1451 non-displaceable binding potential
(BPND), a measure of speciﬁc binding, was determined for each
Hammers atlas region of interest using a basis function imple-
mentation of the simpliﬁed reference tissue model (SRTM)
operating upon the Hammers atlas and reference tissue
region of interest data, both with and without CSF correction
(Gunn et al., 1997). 11C-PiB data were treated as dichotomous
measures (i.e. positive or negative) and considered positive if
the ratio of the average SUVR values across the cortical and
cerebellar regions of interest was41.5, as previously described
(Hatashita and Yamasaki, 2013).
PET statistical analyses
To compare 18F-AV-1451 binding across groups (Alzheimer’s
disease/MCI PiB+ , PSP, and controls), individual region of inter-
est BPND values for
18F-AV-1451 were used in a repeated-meas-
ures general linear model (GLM) to test for the main effect of
region of interest, main effect of group, and group  region of
interest interaction. Age and education were included as covari-
ates of no interest. For the Alzheimer’s disease/MCI PiB+ and
PSP groups, we tested for correlations between regional 18F-AV-
1451 BPND and disease severity using the ACE-R scores for
Alzheimer’s disease/MCI PiB+ patients and the Progressive
Supranuclear Palsy Rating Scale for PSP patients with Pearson’s
correlation (with partial correlations accounting for age and edu-
cation). All analyses were repeated using 18F-AV-1451 BPND
values that were not corrected for CSF partial volume effects.
To assess the ability of 18F-AV-1451 BPND to distinguish
Alzheimer’s disease patients from PSP cases, subject-speciﬁc 18F-
AV-1451 data in a set of regions of interest were input as key
features in a support vector machine (SVM), a multivariate super-
vised statistical learning method suitable for neuroimaging mod-
alities (Cortes and Vapnik, 1995). A reduced group of regions of
interest considered as the most characteristic regions of interest
affected by tau pathology in Alzheimer’s disease and PSP was
selected (i.e. superior/inferior temporal cortex, lateral occipital
cortex, inferior parietal cortex, and hippocampus for
Alzheimer’s disease, and basal ganglia and midbrain for PSP);
noting that the regions of interest included in the SVM were
identical for both groups. This extended the whole-brain hierarch-
ical cluster analysis described in the Supplementary material. The
accuracy of each region of interest to discriminate between the
Alzheimer’s disease and PSP groups was computed using an SVM
classiﬁer with a K means cross-validation (K = 5) scheme with a
linear kernel and standard cost parameter of 1.
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Neuropathological methods
Tissue samples preparation
Post mortem brain tissue from three subjects (one Alzheimer’s
disease case, one PSP patient, and one healthy control with simi-
lar age) from the Cambridge Brain Bank was included in this
study. The autoradiographic and immunohistochemical analyses
were conducted in different cases from those included in the PET
in vivo study. Tissue collection was approved by the local insti-
tutional review board. Neuropathological diagnoses were per-
formed according to standardized protocols, on 15 blocked
regions of cortex and subcortical regions. For this study, add-
itional blocks of frozen brain tissue were obtained from the an-
terior hippocampus, midbrain, basal ganglia, and frontal cortex.
Sections (20-mm thick) were cut in a cryostat (Leica CM30505 S
Research Cryostat) mounted on Thermo Scientiﬁc superfrost plus
slides and used for 18F-AV-1451 phosphor screen, phosphory-
lated-tau immunoreactivity (AT8), and tinctorial stain for neuro-
melanin (Masson-Hamperl stain).
18F-AV-1451 phosphor screen autoradiography
18F-AV-1451 for autoradiographic studies was synthesized in
the same way as described above. 18F-AV-1451 phosphor
screen autoradiography was performed following a previously
published protocol by Marquie` and collaborators (2015). In
brief, 20 mm-thick frozen brain sections were ﬁxed in 100%
methanol at room temperature for 20min and then transferred
to a bath containing high speciﬁc activity 18F-AV-1451 in
10mM phosphate-buffered saline (PBS) with a radioactivity
concentration of 20 mCi/ml. Adjacent brain slices were
placed in a bath that was identical in all aspects except that
unlabelled AV-1451 was added to yield 1 mM chemical con-
centration, a blocking condition sufﬁcient to saturate essen-
tially all available speciﬁc binding sites of tau. After
incubation for 60min, racks of slides were removed from the
respective radioactive solutions and brieﬂy incubated in a
series of wash baths to remove unbound radiotracer. Wash
solutions and incubation times were: 10mM PBS for 1min,
70% ethanol/30% PBS for 2min, 30% ethanol/70% PBS for
1min, and lastly 100% 10mM PBS for 1min. Racks were
removed from the ﬁnal wash solution, and slides were allowed
to air dry before transfer to a storage phosphor screen (GE
healthcare) that had been photobleached immediately before
by exposure on a white light box for a minimum of 15min.
The slides and phosphor screen were enclosed in an aluminium
ﬁlm cassette and set away from sources of radioactivity for the
duration of the overnight exposure period. The cassette was
opened and the slides were removed from the exposed screen,
which was mounted on the digital imaging system (CR 35
BIO, Durr medical). Scanning of screens was controlled by
Aida Image Analyser v.4.27 using 600 dpi resolution
(42 mm sampling interval). Digital images were saved at full
resolution and pixel depth. Images from adjacent brain slices
incubated in the unblocked (high speciﬁc activity 18F-AV-1451
only) and blocking (18F-AV-1451 plus 1mm unlabelled AV-
1451) conditions were compared to estimate total and non-
speciﬁc binding of 18F-AV-1451.
Results
Demographics and cognitive
variables of patients in the PET
in vivo study
There were no statistically signiﬁcant differences between
patient and control groups in terms of age or sex
(Table 1). Shorter education was reported by patients
with PSP relative to other groups (Table 1). One interpret-
ation of this difference is that control cohorts over-repre-
sent people from higher socio-economic groups and with
longer education; however, low education and its effects on
health may also be a risk factor for the development of PSP
(Litvan et al., 2016). Age and education were included as
covariates of no interest in the statistical models assessing
the main effect of region, main effect of group, and group
 region of interest interactions. As expected, there was a
signiﬁcant main effect of group for cognitive measures,
driven by reduced MMSE and ACE-R scores in
Alzheimer’s disease/MCI + and PSP patients relative to
healthy controls (Table 1).
18F-AV-1451 binding in relation to
clinical diagnosis
The mean 18F-AV-1451 BPND PET map in each group
(Fig. 1) and quantitative region of interest analyses (Fig. 2),
indicated high 18F-AV-1451 binding in the basal ganglia in all
groups including controls. In the repeated-measures ANOVA
Table 1 Participant details and group differences by one-way ANOVA or chi-squared test
AD/MCI + (n = 15) PSP (n = 19) Healthy controls (n = 13) Group difference
Sex (male/female) 9/6 11/8 6/7 N/S
Age, years (SD, range) 71.6 (8.7, 54–85) 69.5 (5.8, 52–79) 67.2 (7.3, 55–80) F = 1.2, P = 0.3
Education, years (SD, range) 14.3 (3.3, 10–19) 11.9 (1.8, 10–17) 15.8 (1.9, 11–19) F = 10.2, P = 0.0003
MMSE (SD, range) 25.5 (2.8, 18–28) 26.1 (4.5, 13–30) 29.3 (0.7, 28–30) F = 4.9, P = 0.012
ACE-R (SD, range) 75.9 (11.0, 51–89) 78.7 (15.8, 36–95) 95.5 (3.0, 89–99) F = 10.3, P = 0.0002
PSP Rating Scale (SD, range) – 43.6 (15.8, 15–74) – –
Values are mean (SD, range).
AD/MCI + = Alzheimer’s disease/mild cognitive impairment (amyloid-positive from PiB-PET scan); MMSE = Mini-Mental State Examination; ACE-R = Addenbrookes’ Cognitive
Examination, Revised. N/S = not significant at P5 0.05 (uncorrected).
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of regional binding, we found a signiﬁcant main effect of
group [F(2,41) = 17.5, P = 0.00001] and a region of inter-
estgroup interaction [F(2,68) = 7.5, P5 0.00001], although
there was no main effect of regions of interest [F(2,34) = 0.8,
P = 0.8] (Fig. 2). The group and interaction effects were
driven in part by greater 18F-AV-1451 BPND in the
Alzheimer’s disease/MCI+ group relative to the PSP and con-
trol groups, in cortical and subcortical areas including frontal,
parietal, lateral temporal, and occipital cortices as well as the
hippocampus and other medial temporal lobe regions (post
hoc t-tests, t’s4 2.2, P’s5 0.04) (Fig. 2). The PSP group,
relative to the Alzheimer’s disease group, showed increased
18F-AV-1451 BPND in the midbrain (t = 2.1, P50.04);
while, relative to controls, PSP patients showed increased
18F-AV-1451 BPND in the putamen, pallidum, thalamus, mid-
brain, and dentate nucleus of the cerebellum (t’s4 2.7,
P5 0.02) (Fig. 2).
Repeating the analyses using 18F-AV-1451 BPND values
that were not corrected for CSF partial volume effects
yielded similar results [F(2,36) = 1.1, P = 0.2, for the main
effect of regions of interest; F(2,41) = 16.7, P5 0.00001 for
the main effect of group; and F(2,72) = 6.3, P5 0.00001
for the group  region of interest interaction]. We then
tested whether regional 18F-AV-1451 BPND related to dis-
ease severity. In the Alzheimer’s disease/MCI + group, there
was no signiﬁcant correlation between ACE-R score and
18F-AV-1451 BPND in any region of interest (P’s4 0.14).
Similarly, in the PSP group, we found no signiﬁcant correl-
ation between 18F-AV-1451 BPND in any region of interest
and disease severity, as assessed via the Progressive
Supranuclear Palsy Rating Scale (P’s4 0.16). Repeating
the correlation analyses when using the 18F-AV-1451
BPND values that were not corrected for CSF volume
yielded similar non-signiﬁcant results (P’s4 0.1).
Classification of cases by 18F-AV-1451
BPND
The SVM analysis using 18F-AV-1451 BPND values in a
subset of regions of interest was able to separate the
Alzheimer’s disease/MCI + patients from PSP cases with a
classiﬁcation accuracy of 94.1%. The accuracy for the
other pair-wise comparisons is as follows: Alzheimer’s dis-
ease/MCI + versus controls = 85.7%; PSP versus con-
trols = 90.6% (Fig. 3 for data plot from two characteristic
regions of interest). In the Supplementary material we also
report the accuracy of pair-wise comparisons between
groups using hierarchical cluster analyses, based on the re-
gional distribution of 18F-AV-1451 BPND across the whole




A summary of the autoradiography results, AT8 immuno-
histochemistry data, and neuromelanin staining in post
mortem Alzheimer’s disease, PSP, and control case is
shown in Fig. 4.
Figure 1 BPND for
18F-AV-1451 for Alzheimer’s disease, including PiB positive MCI, PSP, and healthy controls. Note the 18F-AV-
1451 binding in the basal ganglia in all groups, albeit higher in Alzheimer’s disease and PSP patients. Patients with Alzheimer’s disease also showed
increased 18F-AV-1451 binding in medial temporal lobe regions and widespread neocortical areas, relative to controls and PSP patients, while PSP
patients had increased high 18F-AV-1451 binding to the midbrain, relative to patients with Alzheimer’s disease and control subjects (see Fig. 2 and
‘Results’ section in the main text for quantitative analyses).
6 | BRAIN 2017: Page 6 of 11 L. Passamonti et al.
The autoradiography phosphor screen analyses in the
Alzheimer’s disease brain tissue sample revealed that the
hippocampus had the highest and most speciﬁc binding of
the 18F-AV-1451 radiotracer. 18F-AV-1451 binding was
also found in the frontal cortex in the Alzheimer’s disease
case, although to a lesser extent than in the hippocampal
slice. In contrast, sparse and non-speciﬁc 18F-AV-1451
binding was found in the Alzheimer’s disease basal ganglia
tissue.
The PSP and control tissues showed overall sparse and
non-speciﬁc 18F-AV-1451 binding, including hippocampus,
midbrain, basal ganglia, and frontal cortex.
Figure 2 Mean (SD) 18F-AV-1451 BPND in each region of interest for the participant groups: Alzheimer’s disease and
amyloid-positive MCI; PSP, and healthy controls. The 18F-AV-1451 BPND data reported here are corrected for CSF volume. See the
‘Results’ section for statistics related to CSF corrected and uncorrected data. AD = Alzheimer’s disease; MCI + = amyloid-positive MCI; HC =
healthy control.
Figure 3 Individual 18F-AV-1451 BPND values in the hippocampus (x-axis) and midbrain (y-axis) in patients with Alzheimer’s
disease (AD) and amyloid-positive MCI (MCI + ; red dots), PSP (cyan dots), and healthy control subjects (green dots). Note the
clear bivariate separation of AD/MCI + from PSP patients.
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Abundant hyperphosphorylated tau protein was detected
in the hippocampus of the Alzheimer’s disease case, while
small and punctate tau staining was found in the midbrain
and frontal cortex of the same patient, which is overall
consistent with the results of the phosphor screen autoradi-
ography. Although hyperphosphorylated tau protein was
found in the frontal cortex in the Alzheimer’s disease
case, its relatively low density could be due to a slow cor-
tical disease progression in this particular patient.
The PSP tissue displayed high concentration of hyperpho-
sphorylated tau in the midbrain and basal ganglia, while
the Alzheimer’s disease brain displayed little AT8 staining
in the basal ganglia.
As expected, the control brain did not show AT8 immu-
noreactivity in any of the regions of interest examined.
Neuromelanin-containing cells were only observed in the
midbrain in all post mortem cases. Of note, no neurome-
lanin-containing cells were found in the basal ganglia in
either the Alzheimer’s disease, PSP or control case, which
is in contrast to the strong in vivo 18F-AV-1451 binding of
this radiotracer to the same region of interest.
Discussion
The principal result of our study is that PET imaging with
the radiotracer 18F-AV-1451 revealed distinct patterns of
binding in Alzheimer’s disease and its prodromal state of
MCI, in comparison to the primary tauopathy of PSP. The
relatively large size of our PET study conﬁrmed the high
accuracy of discrimination between the clinical groups
using 18F-AV-1451 BPND data, with a simple support
vector machine and indeed by visual inspection (Figs 1, 2
and 3). However, despite this heuristic potential of 18F-AV-
1451 as a tau biomarker, caution in the interpretation of its
binding targets is indicated by the neuropathological and
autoradiographic data (Marquie` et al., 2015). In particular,
while 18F-AV-1451 strongly bound to Alzheimer’s disease-
related tau pathology, non-speciﬁc binding of the same
tracer can be found in patients with PSP and control sub-
jects (Marquie` et al., 2015). Nevertheless, our post mortem
data suggest that off-target binding to neuromelanin is not
a sufﬁcient explanation of the BPND for
18F-AV-1451, at
least in the context of PSP, and in some critical regions as
the basal ganglia. For instance, we found in vivo signiﬁcant
18F-AV-1451 binding in the basal ganglia (in all groups
including controls) in the absence of post mortem neuro-
melanin-containing cells. This indicates that neuromelanin
is not the principal target of off-target binding for 18F-AV-
1451, but there may be other off-target binding sites that
have as yet not been identiﬁed, including non-tau targets in
disorders associated with predominantly TDP-43 pathology
(Bevan-Jones et al., 2016c).
For 18F-AV-1451 PET to meet its full potential as a bio-
marker to stratify or monitor the effect of disease-modify-
ing drugs in future clinical trials, additional properties
would therefore need to be established. In particular, fur-
ther work is needed to demonstrate changes in 18F-AV-
1451 PET over time, or in response to treatment. A
cross-sectional study as this one cannot be used to infer
Figure 4 Post mortem data. The figure aligns the 18F-AV-1451
autoradiographic binding in key regions of interest in an Alzheimer’s
disease (AD) case, a patient with PSP, and a control of similar age.
Immunohistochemistry data assessing hyperphosphorylated tau
(AT8, red), and neuromelanin staining (dark brown) are also shown
for the same cases and regions of interest. There is 18F-AV-1451
binding in the hippocampus and, to a lesser extent, in the frontal
cortex in Alzheimer’s disease. In contrast, 18F-AV-1451 binding to
the midbrain slices was not specific to PSP but was also detected in
the Alzheimer’s disease and control cases, who showed little or no
tau pathology in the midbrain. Despite the in vivo 18F-AV-1451
binding to the basal ganglia in all groups (including controls, see Figs
1 and 2), post mortem 18F-AV-1451 binding to the basal ganglia was
sparse and non-specific in these three cases. Note the absence of
neuromelanin-containing cells in the basal ganglia and cortical re-
gions. The magnification of the immunohistochemistry pictures
(AT8) and neuromelanin staining is 20.
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longitudinal changes, but it can be employed to inform and
model a biomarker’s potential. More speciﬁcally, the rele-
vance of 18F-AV-1451 is increased by the demonstration
that its binding patterns recapitulate in vivo the established
post mortem distributions of tau pathology in Alzheimer’s
disease and PSP. In addition, 18F-AV-1451 PET may have
biomarker potential for the differential diagnosis of equivo-
cal cases: while the distinction between Alzheimer’s disease
and PSP can be readily made on clinical grounds, patients
with PSP-parkinsonism clinically resemble Parkinson’s dis-
ease (Williams et al., 2005).
In contrast to previous results (Johnson et al., 2016;
Ossenkoppele et al., 2016), 18F-AV-1451 binding was not
correlated with disease severity in our groups (i.e. severity
of cognitive impairment in patients with Alzheimer’s dis-
ease and Progressive Supranuclear Palsy Rating Scale in
patients with PSP). There are several possible explanations
for the lack of a correlation in our study, including lack of
statistical power (type II error) or the use of clinical meas-
ures that were not sufﬁciently sensitive to describe the full
spectrum of clinical variability in Alzheimer’s disease and
PSP. Alternatively, it may be that 18F-AV-1451 binding is
inherently limited in staging disease severity in Alzheimer’s
disease and PSP, analogous to the PiB tracer in Alzheimer’s
disease (Hatashita and Yamasaki, 2010).
Technical considerations in assessing the 18F-AV-1451
binding post mortem and in estimating BPND in vivo
must also be discussed. First, it is possible that in the auto-
radiographic protocol (Marquie´ et al., 2015), ethanol
washing, and other procedures may have affected the label-
ling with 18F-AV-1451, especially in the basal ganglia.
Second, our PET analyses employed correction of ‘partial
volume effects’, resulting from CSF volume within each
region. This mitigates the potential inﬂuence of brain
volume loss seen in Alzheimer’s disease and PSP.
Nevertheless, using uncorrected PET data yielded qualita-
tively similar results in terms of the main effect of group
and group  region of interest interaction, which suggests
that we avoided ‘over-correcting’ the BPND values based on
cortical and subcortical atrophy, and the consequent infer-
ential error from CSF volume and its correction.
Interestingly, the regions with the most signiﬁcant group
differences in 18F-AV-1451 BPND in Alzheimer’s disease
and PSP in vivo were those predicted from prior post
mortem studies for each disease. More speciﬁcally, the
clinical syndromes of Alzheimer’s disease and biomarker
positive MCI were associated with increased 18F-AV-1451
BPND in widely distributed sub-cortical and cortical areas
that have been consistently implicated in the pathogenesis
and progression of Alzheimer’s disease (e.g. hippocampus,
amygdala as well as frontal, parietal, temporal, and occipi-
tal cortices) (Braak and Braak, 1995). Conversely, PSP was
associated with a pattern of increased 18F-AV-1451 BPND
in the basal ganglia, midbrain, and dentate nucleus of the
cerebellum, consistent with the pathophysiology of the dis-
ease (Hauw et al., 1994; Litvan et al., 1996a, b). Together,
these data demonstrated that the 18F-AV-1451 ligand
recapitulates in vivo the typical neuropathological changes
seen in Alzheimer’s disease and PSP, although it cannot be
assumed that the cellular and/or molecular targets of 18F-
AV-1451 binding are the same in both disorders.
18F-AV-1451 BPND in selected regions of interest also
distinguished Alzheimer’s disease cases from PSP patients
with an accuracy of 94% which suggests the potential of
this radio-tracer to discriminate in vivo among different
tauopathies. The value of this analysis is obviously not as
a diagnostic biomarker, as clinical features readily distin-
guish the groups, but rather represents an early step in the
process of validating 18F-AV-1451 PET as a biomarker for
tauopathies. Multicentre replication with larger samples
and broader diagnostic spectra are necessary, including
for example, patients with frontotemporal dementia, corti-
cobasal syndrome, or presymptomatic individuals with high
risk of developing tau-related neurodegenerative disorders
(e.g. carrying speciﬁc gene mutations).
Finally, we note that our data are speciﬁc to 18F-AV-
1451, and do not necessarily generalize to other radioli-
gands. Further work is required to determine the speciﬁcity
of 18F-AV-1451 and other candidate ligands’ binding to the
different isoforms of tau protein, their differential modes of
modiﬁcation (e.g. phosphorylation, acetylation) and aggre-
gation (e.g. oligomeric states or neuroﬁbrillar tangles).
These issues are of high relevance for this and other studies
because: (i) Alzheimer’s disease is characterized by balanced
3R/4R isoforms, while PSP pathology is mainly a 4R iso-
form tauopathy (Bue´e and Delacourte, 1999; Espinoza
et al., 2008), and (ii) the toxicity of tau aggregates may
be driven by oligomers rather than tangles.
In conclusion, we suggest that 18F-AV-1451 is a useful
PET ligand for in vivo studies in clinical populations with
Alzheimer’s disease pathology and non-Alzheimer’s disease
primary tauopathies such as PSP, despite the potential con-
tribution of non-speciﬁc or ‘off-target’ binding. The brain
regions with increased 18F-AV-1451 binding were those
predicted from the well-established patterns of neurodegen-
eration in both diseases, and are in keeping with the cog-
nitive and motor features classically seen in Alzheimer’s
disease and PSP clinical syndromes, respectively. Together,
our current ﬁndings support the further use of 18F-AV-
1451 PET in vivo and in vitro to evaluate tau pathology
in studies of dementia and neurodegeneration.
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